Clinical trials: Chronic Myocardial Ischemia
Coronary Heart Disease
Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)
Testosterone has traditionally been regarded as a risk factor for heart disease due to the fact that males have a higher incidence of this disease than women, at least until the menopause.
- Trial name
- NCT00239590
- Testing
- Testosterone undecanoate
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Imperial College London
Asthma, Coronary Artery Disease
A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.
- Conditions
- Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
- Trial name
- NCT00862641
- Testing
- Regadenoson
- Where
- 48 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Astellas Pharma Inc
Chronic Coronary Syndrome, Hypertension
Benidipine in Hypertensive and/or Chronic Coronary Syndrome Patients
Evaluation of the clinical outcomes of Benidipine initiated by physician's preference in patients with hypertension and/or angina pectoris (chronic coronary syndrome) presenting to cardiology outpatient clinics in Türkiye.
- Conditions
- Chronic Coronary Syndrome, Hypertension, Angina Pectoris
- Trial name
- BenidipineTR (NCT06808321)
- Testing
- Benidipine Hydrochloride
- Where
- Turkey (Türkiye)
- Volunteers
- 1,659 people
- Sponsor
- The Society of Prevention and Awareness of Cardiovascular Diseases
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences
Coronary Syndrome
WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?
The trial is a pharmacodynamic study to determine the effect of a novel regimen of aspirin 20 mg BD plus rivaroxaban 2.5 mg BD on haemostasis, fibrin clot dynamics, inflammatory markers, platelet function and arachidonic acid…
- Trial name
- WILLOW CCS (NCT04990791)
- Testing
- Aspirin 75mg, Aspirin 20mg, Rivaroxaban 2.5 mg
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Angina
Ranolazine Among Unrevascularized Chronic Stable Angina Patients
This is a prospective, double-blind, placebo-controlled, randomized, single-center (North Florida- South Georgia VA Medical Center) study.
- Trial name
- IMWELL (NCT02265796)
- Testing
- Ranolazine, Sugar pill
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- North Florida Foundation for Research and Education
Chronic Obstructive Pulmonary Disease, Heart Failure
PATient Navigator to rEduce Readmissions
Staying out of the hospital is valued by patients and their caregivers. Their interests converge with those of hospitals now that high 30-day readmission rates for some conditions place hospitals at risk for financial penalties…
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Sickle Cell Disease, Myocardial Infarction
- Trial name
- PArTNER (NCT02114515)
- Testing
- Hospital usual care, Navigator intervention, Peer-led telephone support line
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- University of Illinois Chicago
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease
EXCEL Clinical Trial
To establish the safety and efficacy of the commercially approved XIENCE Family Stent System (inclusive of XIENCE PRIME, XIENCE V, XIENCE Xpedition and XIENCE PRO [for use outside the United States [OUS] only]) in subjects with…
- Conditions
- Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease
- Trial name
- EXCEL (NCT01205776)
- Testing
- Percutaneous Coronary Intervention, CABG
- Where
- United States
- Volunteers
- 1,905 people
- Sponsor
- Abbott Medical Devices
Chronic Total Occlusion of Coronary Artery, Coronary Occlusion
ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.
ABSORB FIRST is a prospective, multi-center registry. The objectives of the study are to: Provide ongoing post-market surveillance for documentation of safety, performance and clinical outcomes of the Absorb BVS (Bioresorbable…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Coronary Occlusion, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT01759290
- Testing
- Absorb Bioresorbable Vascular Scaffold
- Where
- Belgium
- Volunteers
- 1,800 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Prasugrel Re-load Strategies
A higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease.
- Trial name
- NCT01201772
- Testing
- Prasugrel
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Chronic Total Occlusion, Ischemic Heart Disease
Chronic Total Occlusion Percutaneous Coronary Intervention Study
The objective of this study is to evaluate angiographic confirmation of placement of any guidewire beyond the CTO, in the true vessel lumen, in patients undergoing CTO percutaneous coronary intervention (PCI) in which at least…
- Conditions
- Chronic Total Occlusion, Ischemic Heart Disease, Chronic Total Occlusion of Coronary Artery
- Trial name
- CTO-PCI (NCT03988166)
- Testing
- Chronic Total Occlusion Revascularization, GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vascular Solutions LLC
Chronic Stable Angina
Phase IIb Study of STA-2 in Patients With Chronic Stable Angina
The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.
- Trial name
- NCT01239511
- Testing
- green tea polyphenols (STA-2)
- Where
- 5 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- Sinphar Pharmaceutical Co., Ltd
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases, Atherosclerosis
Aspirin Dose and Atherosclerosis in Patients With Heart Disease
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients who have had a heart attack.
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
- Trial name
- TAD (NCT00272337)
- Testing
- Aspirin
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Florida Atlantic University
Cardiovascular Diseases, Adherence, Medication
Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications
The study plans to learn if sending different text messages, serving as reminders or encouragement, may help patients take their medication more often if they have had trouble keeping up with their medicines.
- Conditions
- Cardiovascular Diseases, Adherence, Medication, Medication Adherence, Diabetes Mellitus
- Trial name
- NCT03973931
- Testing
- Nudge
- Where
- 4 sites in United States
- Volunteers
- 9,501 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Chronic Stable Angina, Refractory Angina
Wave Crossover ECP Study for Simplified Therapy
The purpose of this study is to demonstrate substantial equivalence between Pression's Wave PRO System and a commercially available predicate ECP device to support a U.S. 510(k) submission for the Wave PRO System.
- Trial name
- WaveCRESST (NCT06571370)
- Testing
- External Counterpulsation
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Pression
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)
Thirty (30) patients with chronic ischemic left ventricular dysfunction secondary to MI scheduled to undergo cardiac catheterization will be enrolled in the study.
- Trial name
- Trident (NCT02013674)
- Testing
- Allogeneic hMSCs
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua M Hare
Heart Disease (Coronary Artery Disease, Ischemic Heart Disease, Hypertensive Heart Disease), Uncontrolled Diabetes (HBA1c ≥ 10)
Piloting the IPROACTIF Program to Preserve Functioning and Prevent Cognitive Decline
Conduct a pilot randomized control to assess the preliminary efficacy of IPROACTIF, an occupational therapist-delivered primary care intervention for aging and chronic disease management.
- Trial name
- NCT04682977
- Testing
- IPROACTIF (Integrated PRimary Care and Occupational Therapy for Aging and Chronic Disease Treatment to preserve Independence and Functioning), Usual primary care services
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Illinois Chicago